Contributor
Max Rex
Menu
Max Rex
Its almost six months since President Joe Biden came to office but the role of the head of the country’s key drug regulator, the US Food and Drug Administration (USFDA) is yet to be filled. In this episode, the P4A discusses the absence of a USFDA commissioner and its impact. Also, we understand the significance of recent remarks of the Center for Biologics Evaluation and Research (CBER) director Peter Marks on the need for consistency in the manufacture of cell and gene therapies.
Presenter and Contributor: Max Rex
Producer: Aparna Krishnan
